--- title: Future of pharma theatre --- This is a search field with an auto-suggest feature attached. - There are no suggestions because the search field is empty. - [Careers](https://www.siegfried.ch/careers/) - [Media](https://www.siegfried.ch/media/) - [Investors](https://www.siegfried.ch/investors/) - [Contact us](https://www.siegfried.ch/contact/) [Company](https://www.siegfried.ch/company/) Company [Purpose](https://www.siegfried.ch/company/purpose/) [Strategy](https://www.siegfried.ch/company/strategy/) [Leadership](https://www.siegfried.ch/company/leadership/) [History](https://www.siegfried.ch/company/history/) [Locations](https://www.siegfried.ch/company/locations/) [Offering](https://www.siegfried.ch/offering/) Offering [Drug Substances](https://www.siegfried.ch/offering/drug-substances/) [Exclusive synthesis](https://www.siegfried.ch/offering/drug-substances/exclusive-synthesis/) [API portfolio](https://www.siegfried.ch/offering/drug-substances/api/) [Reference standards](https://www.siegfried.ch/reference-standards/) [Preclinical and early-phase development](https://content.siegfried.ch/siegfried-acceleration-hub?hsLang=en) [Alkaloid raw materials extraction](https://extractas.com.au/) [Drug Products](https://www.siegfried.ch/offering/drug-products/) [Oral solid dosage forms](https://www.siegfried.ch/offering/drug-products/oral-solids/) [Sterile injectables](https://www.siegfried.ch/offering/drug-products/sterile-injectables/) [Ophthalmics](https://www.siegfried.ch/offering/drug-products/ophthalmics/) [Inhalation products](https://www.siegfried.ch/offering/drug-products/inhalatives/) [Viral vectors](https://dinamiqs.com/) [Technologies](https://www.siegfried.ch/technologies/) [Sustainability](https://www.siegfried.ch/sustainability/) Sustainability [People](https://www.siegfried.ch/sustainability/people/) [Environment](https://www.siegfried.ch/sustainability/environment/environment/) [Integrity](https://www.siegfried.ch/sustainability/integrity/) [Quality](https://www.siegfried.ch/sustainability/quality/) [Community engagement](https://siegfried.ch/sustainability/community-engagement/) [Risk management](https://www.siegfried.ch/sustainability/risk-management/) [Insights](https://content.siegfried.ch/insights?hsLang=en) [![](https://content.siegfried.ch/hubfs/siegfried-logo.svg)](https://www.siegfried.ch/) What are you looking for? [![](https://content.siegfried.ch/hubfs/siegfried-logo.svg)](https://www.siegfried.ch/) [Company](https://www.siegfried.ch/company/) [Purpose](https://www.siegfried.ch/company/purpose/) [Strategy](https://www.siegfried.ch/company/strategy/) [Leadership](https://www.siegfried.ch/company/leadership/) [History](https://www.siegfried.ch/company/history/) [Locations](https://www.siegfried.ch/company/locations/) [Offering](https://www.siegfried.ch/offering/) [Drug Substances](https://www.siegfried.ch/offering/drug-substances/) [Exclusive synthesis](https://www.siegfried.ch/offering/drug-substances/exclusive-synthesis/) [API portfolio](https://www.siegfried.ch/offering/drug-substances/api/) [Reference standards](https://www.siegfried.ch/reference-standards/) [Preclinical and early-phase development](https://content.siegfried.ch/siegfried-acceleration-hub?hsLang=en) [Alkaloid raw materials extraction](https://extractas.com.au/) [Drug Products](https://www.siegfried.ch/offering/drug-products/) [Oral solid dosage forms](https://www.siegfried.ch/offering/drug-products/oral-solids/) [Sterile injectables](https://www.siegfried.ch/offering/drug-products/sterile-injectables/) [Ophthalmics](https://www.siegfried.ch/offering/drug-products/ophthalmics/) [Inhalation products](https://www.siegfried.ch/offering/drug-products/inhalatives/) [Viral vectors](https://dinamiqs.com/) [Technologies](https://www.siegfried.ch/technologies/) [Sustainability](https://www.siegfried.ch/sustainability/) [People](https://www.siegfried.ch/sustainability/people/) [Environment](https://www.siegfried.ch/sustainability/environment/environment/) [Integrity](https://www.siegfried.ch/sustainability/integrity/) [Quality](https://www.siegfried.ch/sustainability/quality/) [Community engagement](https://siegfried.ch/sustainability/community-engagement/) [Risk management](https://www.siegfried.ch/sustainability/risk-management/) [Insights](https://content.siegfried.ch/insights?hsLang=en) - [Careers](https://www.siegfried.ch/careers/) - [Media](https://www.siegfried.ch/media/) - [Investors](https://www.siegfried.ch/investors/) - [Contact us](https://www.siegfried.ch/contact/) # Future of Pharma and Ingredients Theatre 28-30 October 2025 Hall 12.1- 12.1C68 ![cphi-logo-rgb-frankfurt-neg](https://content.siegfried.ch/hubfs/cphi-logo-rgb-frankfurt-neg.svg) ![CPHI\_graphic\_element](https://content.siegfried.ch/hubfs/CPHI_graphic_element.svg) ![lightbulb\_siegfried-black-1](https://content.siegfried.ch/hs-fs/hubfs/lightbulb_siegfried-black-1.png?width=40&height=40&name=lightbulb_siegfried-black-1.png) ## 50+ speakers ![arrow-sf-black-2](https://content.siegfried.ch/hs-fs/hubfs/arrow-sf-black-2.png?width=40&height=40&name=arrow-sf-black-2.png) ## 26 sessions ![Frame-2-black-40](https://content.siegfried.ch/hs-fs/hubfs/Frame-2-black-40.png?width=40&height=40&name=Frame-2-black-40.png) ## 3 days ### The Future of Pharma and Ingredients Theatre at CPHI Frankfurt brings together more than 50 industry experts to uncover the trends and technologies transforming pharmaceutical manufacturing. [Explore the agenda](https://www.cphi.com/europe/en/attend/attend/conference-agenda.html?showActions=true&filters=RmllbGREZWZpbml0aW9uXzMzOTE5Ng%253D%253D%3ARmllbGRWYWx1ZV8yNDAyODEzNQ%253D%253D#agenda) ## Faster by design: What’s driving the acceleration of drug development timelines? **October 29 at 15:45** Accelerated timelines are no longer the exception—they’re becoming the norm across the pharma industry. An increasing number of molecules are receiving conditional or expedited approvals, often at earlier stages of development. This trend is reshaping expectations not only for clinical progress but also for CMC, where development windows are tightening significantly. Nearly two-thirds of recent FDA novel drug approvals occurred under an accelerated pathway. In this panel discussion, industry leaders will explore the forces driving this shift. [Add to calendar](https://content.siegfried.ch/hubfs/Faster%20by%20design%20Whats%20driving%20the%20acceleration%20of%20drug%20development%20timelines.ics?hsLang=en) ![Panelists 2](https://content.siegfried.ch/hs-fs/hubfs/Panelists%202.jpg?width=2000&name=Panelists%202.jpg) ## Featured speakers ##### Claire D'Abreu-Hayling ##### Chief Scientific Officer Sandoz Science-Led Regulatory Reform: Accelerating Biosimilar Development to Expand Patient Access to Life-Changing Medicines ##### Maggie Saykali Director EFCG (Cefic) The Critical Medicines Act: Game-Changing Opportunity for a Sustainable and Resilient Supply Chain? ## From lab to launch: Cutting time in pharmaceutical development **October 29 at 13:45** In an industry where drug development often spans over a decade, accelerating timelines is critical—not only to reduce costs but to improve patient access to life-saving therapies. This session explores strategies to streamline the development phase without compromising on safety or quality. Join **Stefan Randl, CSO Siegfried**, to learn how smarter, faster development is both achievable and essential.  [Add to calendar](https://content.siegfried.ch/hubfs/From%20lab%20to%20launch%20Cutting%20time%20in%20pharmaceutical%20development.ics?hsLang=en) ![planning\_banner](https://content.siegfried.ch/hs-fs/hubfs/planning_banner.png?width=920&height=517&name=planning_banner.png) ## Shaping the future of pharma ![Siegfried-Labor-Grey-41-1\_150ppi\_sRGB\_RZ-1](https://content.siegfried.ch/hs-fs/hubfs/Siegfried-Labor-Grey-41-1_150ppi_sRGB_RZ-1.jpg?width=2000&name=Siegfried-Labor-Grey-41-1_150ppi_sRGB_RZ-1.jpg) #### De-risking complexity in pharmaceutical manufacturing Read article ![241213\_Siegfried\_Dinamiqs-776\_RGB\_300ppi](https://content.siegfried.ch/hs-fs/hubfs/241213_Siegfried_Dinamiqs-776_RGB_300ppi.jpg?width=2000&name=241213_Siegfried_Dinamiqs-776_RGB_300ppi.jpg) #### Reexamining process optimization: Advanced analytics for AAV manufacturing Read article ![20230424\_Siegfried\_Barcelona18803\_300ppi\_RGB\_RZ (1)](https://content.siegfried.ch/hs-fs/hubfs/20230424_Siegfried_Barcelona18803_300ppi_RGB_RZ%20(1).jpg?width=2000&name=20230424_Siegfried_Barcelona18803_300ppi_RGB_RZ%20(1).jpg) #### Ask better, move faster: Questions that will accelerate the speed of your program to clinical Read article ![20230424\_Siegfried\_Barcelona18855-gigapixel-standard-scale-2\_00x](https://content.siegfried.ch/hs-fs/hubfs/20230424_Siegfried_Barcelona18855-gigapixel-standard-scale-2_00x.jpg?width=2000&name=20230424_Siegfried_Barcelona18855-gigapixel-standard-scale-2_00x.jpg) #### Quality Engineered: The power of QbD Read article ![Barberba LP photo spray dryer](https://content.siegfried.ch/hs-fs/hubfs/Barberba%20LP%20photo%20spray%20dryer.jpg?width=605&height=403&name=Barberba%20LP%20photo%20spray%20dryer.jpg) #### Maximizing product potential with spray drying Read article ![Siegfried-Labor-Mel-233-1\_150ppi\_sRGB\_RZ-1](https://content.siegfried.ch/hs-fs/hubfs/Siegfried-Labor-Mel-233-1_150ppi_sRGB_RZ-1.jpg?width=2000&name=Siegfried-Labor-Mel-233-1_150ppi_sRGB_RZ-1.jpg) #### Tracking innovation with Siegfried Read article ![20230424\_Siegfried\_Barcelona18921\_300ppi\_RGB\_RZ-1](https://content.siegfried.ch/hs-fs/hubfs/20230424_Siegfried_Barcelona18921_300ppi_RGB_RZ-1.jpeg?width=638&height=298&name=20230424_Siegfried_Barcelona18921_300ppi_RGB_RZ-1.jpeg "20230424_Siegfried_Barcelona18921_300ppi_RGB_RZ-1") ## Get in touch Contact us for more information about Siegfried and our offerings [Contact us](https://www.siegfried.ch/contact-us/) expect more **Siegfried AG** Untere Brühlstrasse 4 4800 Zofingen, Switzerland [+41 62 746 11 11](tel:+41627461111) [Get in touch](https://www.siegfried.ch/contact-us/) #### About us - [Our company](https://www.siegfried.ch/company/) - [Sustainability](https://www.siegfried.ch/sustainability/) - [Media](https://www.siegfried.ch/media/) - [Investors](https://www.siegfried.ch/investors/) - [Careers](https://www.siegfried.ch/careers/) #### Helpful resources - [Expert insights](https://content.siegfried.ch/insights?hsLang=en) - [News archive](https://www.siegfried.ch/news-archive/) - [Reports](https://www.siegfried.ch/investors/investors-download-center-2025/) - [Terms and conditions](https://www.siegfried.ch/terms-and-conditions/) #### Offering - [Drug Substances](https://www.siegfried.ch/offering/drug-substances/) - [Drug Products](https://www.siegfried.ch/offering/drug-products/) - [Technologies](https://www.siegfried.ch/technologies/) 2026 © Siegfried Holding AG - [Privacy Policy](https://www.siegfried.ch/privacy-policy/) - [Legal disclaimer](https://www.siegfried.ch/legal-disclaimer/) - [Imprint](https://www.siegfried.ch/imprint/)